- $182.21bn
- $227.49bn
- $36.75bn
U.S. STOCKS ON THE MOVE-CDW, Destiny Tech100, Avery Dennison
Analysis: Novo Nordisk risks weight-loss price war as discount pressures deepen
U.S. STOCKS ON THE MOVE-Bio-Techne, AbbVie, Johnson Controls
Street View: Amgen banks on pipeline depth and long term weight-loss play
U.S. STOCKS ON THE MOVE-GE Healthcare, Amgen, Lilly
Amgen climbs after upbeat 2026 profit forecast
Amgen results beat Street estimates, shares tick higher (updated)
Amgen up after quarterly results beat Wall Street estimates
Health Rounds: Cancer immunotherapies may be more effective given earlier in the day
Brief: Amgen Reports Fourth Quarter And Full Year 2025 Financial Results
Brief: Amgen Outlook FY Adjusted EPS USD 21.6-23
Brief: Amgen Posts Q4 Total Rev $9.87 Bln VS IBES Estimate $9.47 Bln
Amgen quarterly results beat Street estimates on higher sales, lower tax rate
Obesity stocks slump on Novo's underwhelming 2026 sales forecast (updated)
PREVIEW: Amgen dips with results due after the bell
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
US-listed Novo shares slip after company flags sharp 2026 sales drop
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Focus: Drugmakers turn to AI to speed trials, regulatory submissions